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Background: We performed this retrospective study to assess
the association of mutations in the epidermal growth-factor
receptor (EGFR) gene with metastatic presentation in patients
with advanced non-small-cell lung cancer (NSCLC).
Methods: Data from 125 patients with stage III or IV NSCLC,
who were screened for EGFR mutations between March, 2007,
and June, 2010, were analysed.
Findings: We detected EGFR mutations in exons 18, 19, and 21
in 36 patients (29%). EGFR mutations were predominant in
never-smokers (p < 0.001), patients with adenocarcinoma
(p < 0.001), and female patients (p < 0.001). Analysis of metastatic
site with respect to mutation status showed that pleural metasta-
ses were associated with a high incidence of EGFR mutation
(p = 0.028) – particularly, pleural metastases with minimal effu-
sion (PMME; p = 0.001). Patients with N3 lesions were less likely
to harbour EGFR mutations (p = 0.033). In multivariate analysis,
N3 lesions (p = 0.017) and PMME (p < 0.001) remained significant
factors for EGFR mutations, whereas gender did not (p = 0.805).
Interpretation: Our data indicate that EGFR mutations may be
associated with different presentations of pleural and N3 nodal
metastases in patients with NSCLC.
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Background: There are limited data regarding risk factors for
breast cancer in Pakistan, although it is the most common
female cancer, with an incidence 2.5 times as high as other
countries in the region. This study investigated risk factors for
female breast cancer in a Pakistani population in southern
Punjab.
Methods: A case-control study was done in the fall of 2010,
involving 100 breast-cancer patients and 150 control individuals
who screened negative for breast cancer on mammography. Infor-
mation about demographic characteristics and potential risk fac-
tors for breast cancer was gathered from both groups using a
standard questionnaire. Logistic regression analysis was done to
determine the association of various potential risk factors with
breast cancer.
Findings: In multivariate logistic regression analysis, risk of
breast cancer was significantly increased in women older than 40
years (odds ratio [OR] 2.66, 95% CI 1.16–6.12), with more than four
full-term pregnancies (OR 5.33, 1.96–14.53), married (OR 2.35,
1.34–3.14), living in rural areas (OR 3.86, 1.63–9.13), and postmeno-
pausal (OR 4.19, 1.70–10.36). Breast-cancer risk was significantly
decreased in women with contraceptive use (OR 0.13, 0.02–1.04)
and no family history of breast cancer (OR 0.28, 0.12–0.69). In addi-
tion, no significant association was found between breast-cancer
risk and age at menarche, age at first live birth, age at menopause,
breastfeeding, and history of spontaneous or induced abortion.
Interpretation: The findings of this study suggest that age > 40
years, parity, marital status, locality, menopausal status, contra-
ceptive use, and family history of breast cancer are significantly
associated with breast-cancer risk in Pakistani women in south-
ern Punjab.
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Background: XELOX (combination therapy of capecitabine and
oxaliplatin) is known to cause nausea and vomiting, despite ade-
quate administration of antiemetics. Furthermore, specific risk
factors that may increase the risk of nausea and vomiting are
unknown.
Methods: This was a single-centre, prospective, cohort study.
Patients were recruited on the day of chemotherapy, and were fol-
lowed up after 5 days to assess nausea, vomiting, and use of
antiemetics. Patients were assessed for nausea and vomiting con-
trol, as well as complete response, complete protection, and com-
plete control of antiemetics. Use of delayed and breakthrough
antiemetics were assessed, and multivariable logistic regression
was done to evaluate risk factors that predisposed patients to
nausea and vomiting despite use of antiemetics.
Findings: 156 patients were included in this analysis. The med-
ian age was 60 years (IQR 55–65) with 88 (56.4%) men and 68
(43.6%) women. The proportion of patients achieving complete
response, complete protection, and complete control within 24
hours after chemotherapy was 87.8%, 80.8%, and 62.8%, respec-
tively. These proportions continued to decline throughout the fol-
low-up period to 76.9%, 64.7%, and 48.7%, respectively, at the end
of the 5 days. Patients who had fewer than three risk factors (odds
ratio [OR] 3.13, p = 0.006), who received oxaliplatin less than
100 mg/m2 (OR 3.23, p = 0.009), and who received capecitabine less
than 1500 mg/m2 (OR 5.00, p = 0.04) were more likely to achieve
complete response to antiemetics.
Interpretation: This study showed that an unacceptably high
proportion of patients receiving XELOX were unable to attain
adequate control of nausea. Future research should focus on
the optimisation of antiemetic therapy for patients receiving
XELOX.
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